Chengdu Kanghua Biological Products (300841.SZ): Recombinant hexavalent Norovirus vaccine obtains US FDA approval to enter clinical research.

18:50 07/09/2023

Chengdu Kanghua Biological Products (300841.SZ) announced that the company has received a notification from the US Food and Drug Administration (FDA), approving the company's recombinant hexavalent rotavirus vaccine for clinical research in the United States. The recombinant hexavalent rotavirus vaccine is applicable for the prevention of rotavirus infection and acute gastroenteritis caused by rotavirus. Rotavirus is one of the main pathogens causing acute gastroenteritis outbreaks and epidemics in people of all age groups worldwide. Currently, there are no approved therapeutic drugs or preventive vaccine products for rotavirus available globally.

Pakistan: Iran agrees to allow an additional 20 Pakistani ships to pass through the Hormuz Strait.

EB SECURITIES: NONGFU SPRING (09633) saw accelerated revenue growth in the second half of last year, with sufficient long-term development momentum.

EB SECURITIES: CNOOC Limited (00883) Achieves a New High in Oil and Gas Production and Reserves for 25 Consecutive Years, Showing Resilient Performance in a Period of Declining Oil Prices.

Pakistan: Iran agrees to allow an additional 20 Pakistani ships to pass through the Hormuz Strait.

EB SECURITIES: NONGFU SPRING (09633) saw accelerated revenue growth in the second half of last year, with sufficient long-term development momentum.

EB SECURITIES: CNOOC Limited (00883) Achieves a New High in Oil and Gas Production and Reserves for 25 Consecutive Years, Showing Resilient Performance in a Period of Declining Oil Prices.